Reimagining Medicine
Company overview
Financial review
Conclusions
Appendix
References
CosentyxⓇ sales stabilized; expecting growth in H2
Sales evolution
USD m, % cc
Ex-US
US
+1%
1,275
1,272
539
622
736
650
Q2 2022
Q2 2023
GROWTH
Cosentyx®
Q2 performance
US sales (-12% cc): Volume growth offset by revenue deductions (incl. PY base impact)
Ex-US sales (+18% cc): Strong growth in core indications
China: Outperforming market with double-digit growth post-COVID
Expect growth in H2
EU: HS approved in Q2
US: HS and Rheum IV approvals expected H2
US: 300mg autoinjector approved
LCM program
3 Ph3 studies ongoing: Giant Cell Arteritis, Polymyalgia Rheumatica,
Rotator Cuff Tendinopathy; termination of lupus nephritis
HS-hidradenitis suppurativa. IV - intravenous. Constant currencies (cc), core results are non-IFRS measures; explanation can be found on page 48 of Condensed Interim Financial Report.
7 Investor Relations | Q2 2023 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation